Predicted cumulative incidence of recurrence and of death without recurrence
Prediction at 1, 3 and 5 years after diagnosis, based on patient- and tumor-specific characteristics.
This tool is designed to support discussions between clinicians and patients and to assist with clinical decision-making.
It does not replace professional clinical judgement and should always be considered together with the patient's individual circumstances and overall clinical picture.
It does not replace professional clinical judgement and should always be considered together with the patient's individual circumstances and overall clinical picture.
The predictions apply from the end of the diagnostic assessment period, which in Norway is four months after the initial diagnosis.
Reference: Giorcelli A, Valberg M, Green AC, Veierod MB, Costa DR, Gran JM, Svendsen HL, Jespersen H, Andreassen BK, Robsahm TE, Ghiasvand R. Risk of recurrence of stage I to III melanoma in Norway, 2008–2022. Eur J Cancer. 2026 (in press). doi: 10.1016/j.ejca.2026.116940.